蒲地蓝消炎口服液联合注射用炎琥宁治疗小儿病毒性肺炎的临床研究

目的探讨蒲地蓝消炎口服液联合注射用炎琥宁治疗小儿病毒性肺炎的临床疗效。方法选择2015年2月—2017年2月襄阳市中心医院收治的110例小儿病毒性肺炎为研究对象,依据抽签法将110例患儿随机分为对照组和治疗组,每组各55例。对照组患儿静脉滴注注射用炎琥宁,10 mg/kg加入5%葡萄糖溶液250 m L中,1次/d;治疗组在对照组的基础上口服蒲地蓝消炎口服液,10 mL/次,3次/d。两组患儿均连续治疗10 d。观察两组的临床疗效,比较两组的临床症状改善情况、肺功能、血清炎症因子水平。结果治疗后,对照组和治疗组的总有效率分别为74.55%、90.91%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组患儿退热时间、咽痛消失时间、啰音消失时间、血象恢复时间、止咳时间均显著短于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿最高呼气流速(PEF)、用力肺活量(FVC)、1秒钟用力呼气容积(FEV1)和1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组患儿肺功能指标均显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患儿血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平均显著低于对照组,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组患儿血清炎症因子水平均显著低于对照组,两组比较差异有统计学意义(P0.05)。结论蒲地蓝消炎口服液联合注射用炎琥宁治疗小儿病毒性肺炎临床效果较好,能缓解患儿的临床症状,改善肺功能,降低炎症反应,具有一定的临床推广应用价值。     

小儿消积止咳口服液联合注射用炎琥宁治疗儿童支原体肺炎的临床研究

目的探讨小儿消积止咳口服液联合注射用炎琥宁治疗儿童支原体肺炎的临床疗效。方法选取2016年6月—2017年6月在上海市第十人民医院治疗的支原体肺炎患儿98例,随机分为对照组和治疗组,每组各49例。对照组患儿静脉滴注注射用炎琥宁,每次5~10 mg/kg加入10%葡萄糖溶液55~250 m L,1次/d;治疗组在对照组的基础上口服小儿消积止咳口服液,5岁以下患儿0.2 g/次,大于5岁0.3 g/次,3次/d。两组患儿均治疗7 d。观察两组患儿临床疗效,比较治疗前后两组患儿临床症状消失时间和住院时间以及血清细胞因子水平和C反应蛋白(CRP)水平。结果治疗后,对照组和治疗组临床总有效率分别为77.55%、87.76%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患儿的退热时间、啰音消失时间、咳嗽好转时间和平均住院时间明显短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患儿血清细胞因子水平和CRP水平均明显降低(P0.05);同时治疗组患儿血清细胞因子水平和CRP水平均明显低于对照组(P0.05)。结论小儿消积止咳口服液联合注射用炎琥宁可明显改善支原体肺炎患儿的临床症状,缩短住院时间,具有一定的临床推广应用价值。     

小儿柴桂退热颗粒联合炎琥宁治疗小儿急性上呼吸道感染的临床研究

目的探讨小儿柴桂退热颗粒联合注射用炎琥宁治疗小儿急性上呼吸道感染的临床疗效。方法选取2015年6月—2016年9月北京市门头沟区妇幼保健院收治的急性上呼吸道感染患儿130例,所有患儿按照随机数字表法分为对照组和治疗组,每组各65例。对照组静脉滴注注射用炎琥宁,15 mg/kg加入到5%葡萄糖溶液250 mL中,1次/d。治疗组在对照组基础上口服小儿柴桂退热颗粒,年龄4岁:4 g/次,4~6岁:6 g/次,年龄≥7岁:8 g/次,3次/d。两组患者均连续治疗7 d。观察两组的临床疗效,比较两组的临床症状改善和炎症因子水平。结果治疗后,对照组和治疗组的总有效率分别为81.54%、92.31%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组退热时间、咽肿消退时间和止涕时间明显短于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平均明显降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论小儿柴桂退热颗粒联合注射用炎琥宁治疗小儿急性上呼吸道感染具有较好的临床疗效,可改善患儿的临床症状,减轻炎症反应,具有一定的临床推广应用价值。     

小儿豉翘清热颗粒联合炎琥宁注射液治疗小儿上呼吸道感染的临床研究

目的探讨小儿豉翘清热颗粒联合炎琥宁注射液治疗小儿上呼吸道感染的临床疗效。方法选取2016年1月—2017年1月在郑州大学附属洛阳中心医院接受治疗的小儿上呼吸道感染患者104例,根据治疗方案的差别分为对照组(52例)和治疗组(52例)。对照组患儿静脉滴注炎琥宁注射液,0.2~0.4 mL/kg,1次/d。治疗组在对照组的基础上口服小儿豉翘清热颗粒,1~3岁患儿2~3 g/次,4~6岁患儿3~4 g/次,7~10岁患儿4~6 g/次,3次/d。两组患儿治疗1周。评价两组患儿临床疗效,同时比较治疗前后两组患儿临床症状消失时间和血清学指标变化。结果治疗后,对照组和治疗组总有效率分别为80.65%、98.08%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患儿的退热、止咳、咽喉红肿、腹泻及鼻塞流涕等消失时间均短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患儿血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和降钙素原(PCT)水平均显著降低,同组比较差异具有统计学意义(P0.05);且治疗组患儿降低水平明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论小儿豉翘清热颗粒联合炎琥宁注射液治疗小儿上呼吸道感染疗效显著,可有效改善临床症状及降低血清炎症因子水平,具有一定的临床推广应用价值。     

清肺消炎丸联合阿奇霉素治疗小儿急性支气管炎的临床研究

目的探讨清肺消炎丸联合阿奇霉素片治疗小儿急性支气管炎的临床疗效。方法选取2018年2月—2019年2月恩施土家族苗族自治州中心医院收治的100例急性支气管炎患儿为研究对象,将所有患儿随机分为对照组和治疗组,每组各50例。对照组患儿口服阿奇霉素片,1片/次,1次/d;治疗组患儿在对照组治疗的基础上口服清肺消炎丸,1岁以内小儿:10丸/次,1～3岁:20丸/次,3～6岁:30丸/次,6～12岁:40丸/次,3次/d。两组患儿持续治疗10 d。观察两组的临床疗效,比较两组的临床症状缓解时间、肺功能指标、血气指标、炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为84.00%、96.00%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组患儿咳嗽消失时间、痰鸣音消失时间、肺部啰音消失时间均显著短于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患者第一秒用力呼气容积(FEV1)、最大呼气流量(PEF)和FEV1/用力肺活量(FVC)显著升高,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患者FEV1、PEF和FEV1/FVC明显高于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患者二氧化碳分压(p CO2)水平显著降低,血氧分压(p O2)水平显著升高,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患者血气指标水平明显优于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患者白细胞介素-8(IL-8)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平显著降低,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患者炎性因子水平明显低于对照组,两组比较差异有统计学意义(P0.05)。结论清肺消炎丸联合阿奇霉素片治疗小儿急性支气管炎具有较好的临床疗效,能改善临床症状、肺功能指标和血气指标,降低血清炎性因子水平,具有一定的临床推广应用价值。     

茵栀黄口服液联合还原型谷胱甘肽治疗新生儿黄疸的临床研究

目的研究茵栀黄口服液联合注射用还原型谷胱甘肽治疗新生儿黄疸的临床疗效。方法选取2016年12月—2017年12月在青海省妇女儿童医院进行治疗的100例新生儿黄疸患儿作为研究对象,采用随机数字表法将所有患儿分为对照组和治疗组,每组各50例。对照组患儿静脉滴注注射用谷胱甘肽,0.6 g加入到5%葡萄糖注射液100 mL中,1次/d;治疗组在对照组治疗的基础上口服茵栀黄口服液,2.5 mL/次,3次/d。两组患儿持续治疗2周。观察两组的临床疗效,比较两组的临床症状缓解时间、生化指标水平、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为80.00%、94.00%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组患儿退黄时间、胎便排空时间显著短于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿血清总胆红素(TBIL)、结合胆红素(DBIL)、丙氨酸氨基转移酶(ALT)和天门冬氨酸氨基转氨酶(AST)水平均显著降低,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患儿血清TBIL、DBIL、ALT、AST水平均明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿白细胞介素-1(IL-1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均明显降低,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患儿IL-1、IL-6、TNF-α水平均明显低于对照组,两组比较差异有统计学意义(P0.05)。结论茵栀黄口服液联合注射用还原型谷胱甘肽治疗新生儿黄疸具有较好的临床疗效,能改善患儿临床症状和肝功能,调节血清炎性因子水平,具有一定的临床推广应用价值。     

甲泼尼龙联合拉氧头孢治疗儿童重症社区获得性肺炎的临床研究

目的探讨注射用甲泼尼龙琥珀酸钠联合注射用拉氧头孢钠治疗儿童重症社区获得性肺炎的临床疗效。方法选取2017年8月—2018年8月西安交通大学第一附属医院收治的重症社区获得性肺炎患儿80例作为研究对象,采用随机对照表法将所有患儿分为对照组和治疗组,每组各40例。对照组患儿静脉滴注注射用拉氧头孢钠,40mg/(kg·d),2次/d,静脉滴注30 min以上。治疗组患者在对照组基础上静脉滴注注射用甲泼尼龙琥珀酸钠30 mg/kg,静脉滴注30 min以上。两组患儿均持续治疗7 d。观察两组患者的临床疗效,同时比较两组治疗前后的临床症状改善时间、动脉血气指标和血清炎性因子水平。结果治疗后,治疗组的总有效率为92.50%,显著高于对照组的82.50%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患儿发热缓解时间、憋喘缓解时间、肺部啰音消失时间、咳嗽消失时间均显著短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组动脉血氧饱和度(SaO2)均显著升高,二氧化碳分压(p CO2)显著下降,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组动脉血气指标明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患儿超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);治疗后,治疗组血清炎性因子水平显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论注射用甲泼尼龙琥珀酸钠联合注射用拉氧头孢钠治疗儿童重症社区获得性肺炎具有较好的临床疗效,能够显著改善患儿临床症状和动脉血气指标,降低血清炎性因子水平,具有一定的临床推广应用价值。     

注射用炎琥宁联合乙酰半胱氨酸治疗肺部感染的临床研究

目的探讨注射用炎琥宁联合吸入用乙酰半胱氨酸溶液治疗肺部感染的临床疗效。方法选择2016年1月—2017年1月西宁市第三人民医院收治的肺部感染患者153例为研究对象,随机分为对照组(76例)和治疗组(77例)。对照组雾化吸入吸入用乙酰半胱氨酸溶液,3 m L/次,2次/d。治疗组在对照组治疗基础上静脉滴注注射用炎琥宁,160 mg加入到5%葡萄糖注射液250 m L中,1次/d。两组患者均连续治疗7 d。观察两组的临床疗效,比较两组的临床肺部感染评分(CPIS)、白细胞计数、临床症状、肺部X片恢复时间和炎症因子水平。结果治疗后,对照组和治疗组的总有效率分别为85.53%、97.40%,两组比较差异有统计学意义(P0.05)。治疗后,两组CPIS和白细胞计数均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组体温恢复时间、咳痰消失时间、肺部X片恢复正常时间短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组超敏C反应蛋白(hs-CRP)和降钙素(PCT)水平均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗组炎症因子水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论注射用炎琥宁联合吸入用乙酰半胱氨酸溶液治疗肺部感染具有较好的临床疗效,可改善临床症状,降低炎症反应,安全性好,具有一定的临床推广应用价值。     

散痰宁糖浆联合布地奈德治疗儿童喘息性支气管炎的临床研究

目的研究散痰宁糖浆联合吸入用布地奈德混悬液治疗儿童喘息性支气管炎的临床疗效。方法选取2017年6月—2018年6月天津市儿童医院收治的100例喘息性支气管炎患儿为研究对象,将所有患儿采用随机数字表法分为对照组和治疗组,每组各50例。对照组患儿雾化吸入吸入用布地奈德混悬液,0.5 mg加入到生理盐水3 mL,10 min/次,1次/d。治疗组患儿在对照组治疗的基础上口服散痰宁糖浆,10 mL/次,3次/d。两组患儿均持续治疗10 d。观察两组的临床疗效,比较两组的临床症状缓解时间、肺功能指标水平、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为82.00%、96.00%,两组比较差异有统计学意义(P0.05)。治疗后,治疗组哮鸣音消失时间、热退时间、喘息消失时间和咳嗽消失时间均短于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患儿用力肺活量(FVC)、第一秒用力呼吸容积(FEV1)、FVC/FEV1、最大呼气流量(PEF)水平均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组患儿肺功能指标水平明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患儿白细胞介素-6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平均显著降低,同组治疗前后比较差异具有统计学意义(P0.05);并且治疗组患儿血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P0.05)。结论散痰宁糖浆联合吸入用布地奈德混悬液治疗儿童喘息性支气管炎具有较好的临床疗效,能改善患儿临床症状和肺功能,降低血清炎性因子水平,具有一定的临床推广应用价值。     

磷酸肌酸钠联合复合辅酶治疗手足口病心肌损伤的临床研究

目的探讨注射用磷酸肌酸钠联合注射用复合辅酶治疗小儿手足口病心肌损伤的临床疗效。方法选取2015年10月—2016年10月在华中科技大学同济医学院附属武汉儿童医院治疗的手足口病心肌损伤患儿86例为研究对象,按照随机数表法将患者分为对照组和治疗组,每组各43例。对照组患儿静脉滴注注射用复合辅酶,1/2~1支,1次/d。治疗组患儿在对照组治疗的基础上静脉输注注射用磷酸肌酸钠,1 g加入到0.9%氯化钠注射液50 m L中,1次/d。两组患儿均连续治疗7 d。观察两组患者的临床疗效,比较两组治疗前后的临床症状改善情况、心功能指标、心电图异常发生率和心肌酶谱指标。结果治疗后,对照组和治疗组临床总有效率分别为93.02%、97.67%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组症状消失时间、心电图恢复时间和住院天数明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者心输出量(CO)和左心室射血分数(LEVF)均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组的心功能指标显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者ST-T段改变、房室传导阻滞、窦性心动过速、窦性心动过缓发生率均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组心电图异常发生率显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者的磷酸肌酸激酶(CK)、磷酸肌酸激酶同工酶(CK-MB)、羟丁酸脱氢酶(HBDH)和乳酸脱氢酶(LDH)水平均显著降低,同组治疗前后比较差异有统计学意义(P0.05);且治疗后治疗组心肌酶谱指标水平显著低于对照组,两组比较差异具有统计学意义(P0.05)。结论注射用磷酸肌酸钠联合注射用复合辅酶治疗小儿手足口病心肌损害的疗效显著,可以有效提高心功能指标,改善心电图异常发生率,降低心肌酶谱水平,安全性好,具有一定的临床推广应用价值。     

Interindividual variability in metabolic activation in humans in vivo

In assessing interindividual variability in metabolic activation, the toxic metabolite is often too unstable for conventional analysis. Possible alternatives include a stable product of the reactive metabolite e.g. cysteinyl derivatives of N-acetyl-4-benzoquinoneimine, the toxic metabolite of paracetamol, adducts with DNA or protein, and indirect measurement of the activity of the enzyme(s) producing the active metabolite. An example of the last approach is the use of furafylline, a highly specific inhibitor of human CYP1A2, to determine the extent of the metabolic activation of the cooked food mutagens PhIP and MeIQx. The extent of inhibition, determined from levels of unchanged amine in urine, is an indirect measure of the activity of the activation pathway. Further refinement of this approach, allied to improved measures of the biological process of interest should prove of value in evaluating interindividual variability and its role in the risk assessment process.     

Quantitative in vivo and in vitro sex differences in artemisinin metabolism in rat

1. The pharmacokinetics of the antimalarial compound artemisinin were compared in the male and female Sprague-Dawley rat after single dose i.v. (20 mg.kg) or i.p. (50 mg.kg) administration of an emulsion formulation. 2. Plasma clearance of artemisinin was 12.0 (95% confidence interval: 10.4, 13.0) l.h. kg in the male rat and 10.6 (95% CI: 7.5, 15.0) l.h. kg in the female rat suggesting high hepatic extraction in combination with erythrocyte uptake or clearance. Artemisinin half-life was 0.5 h after both routes of administration in both sexes. Values for plasma clearance and half-lives did not statistically differ between the sexes. 3. After i.p. administration artemisinin AUCs were 2-fold higher in the female compared with male rat (p 0.001). Artemisinin disappearance was 3.9-fold greater in microsomes from male compared with female livers and it was inhibited in male microsomes by goat or rabbit serum containing antibodies against CYP2C11 and CYP3A2 but not CYP2B1 or CYP2E1. 4. The unbound fraction of artemisinin in plasma was lower (p 0.001) in plasma obtained from the male (8.8 2.0%) compared with the female rat (11.7 2.2%). 5. The possibility of a marked sex difference, dependent on the route of administration, has to be taken into account in the design and interpretation of toxicological studies of artemisinin in this species.     

Theophylline kinetics in peripheral tissues in vivo in humans

Several biochemical and cellular effects have been described for methylxanthines under in vitro conditions. However, it is unknown, whether threshold concentrations required to exert these effects are attained in target tissues in vivo. We therefore employed the microdialysis technique for measuring theophylline concentrations in peripheral tissues under in vivo conditions.Following in vitro and in vivo calibration, microdialysis probes were inserted into the medial vastus muscle and into the periumbilical subcutaneous adipose layer of healthy volunteers. Following single oral dose administration of 300 mg or i.v. infusion of 240 mg theophylline, in vivo time courses of theophylline concentrations were monitored in tissues and plasma. Major pharmacokinetic parameters (c_max, t_max, AUC) were calculated for plasma and tissue time courses. The mean AUC_tissue /AUC_plasma-ratio was 0.56 (p.o.) and 0.55 (i.v.) for muscle and 0.55 (p.o.) and 0.72 (i.v.) for subcutaneous adipose tissue.We conclude that microdialysis provides important information on the distribution and the tissue pharmacokinetics of theophylline.Abbreviations FPIA Fluorescence polarisation immuno assay - AUC Area under the curve - t_max Time to peak concentration - c_max Peak concentration     

休克时血中氧自由基的变化

本实验测定10名休克患者血浆和红细胞的丙二醛(MDA)、血浆总抗的氧化活性(AOA)的含量。结果表明:休克病人红细胞膜和血浆 MDA 含量(4.298±0.722;5.348±0.834)与对照组(3.235±0.682;4.356±1.081)比较明显增高(P<0.05);血浆 AOA(39.65±7.858)与对照组(48.21±10.81)比较明显降低(P<0.01)。提示:休克时,患者机体内自由基反应增强是引起组织细胞损伤的原因之一。     

Polymorphisms in genes involved in neurotransmission in relation to smoking

Smoking behavior is influenced by both genetic and environmental factors. The genetic contribution to smoking behavior is at least as great as its contribution to alcoholism. Much progress has been achieved in genomic research related to cigarette-smoking within recent years. Linkage studies indicate that there are several loci linked to smoking, and candidate genes that are related to neurotransmission have been examined. Possible associated genes include cytochrome P450 subfamily polypeptide 6 (CYP2A6), dopamine D₁, D₂, and D₄ receptors, dopamine transporter, and serotonin transporter genes. There are other important candidate genes but studies evaluating the link with smoking have not been reported. These include genes encoding the dopamine D₃ and D₅ receptors, serotonin receptors, tyrosine hydroxylase, trytophan 2,3-dioxygenase, opioid receptors, and cannabinoid receptors. Since smoking-related factors are extremely complex, studies of diverse populations and of many aspects of smoking behavior including initiation, maintenance, cessation, relapse, and influence of environmental factors are needed to identify smoking-associated genes. We now review genetic polymorphisms reported to be involved in neurotransmission in relation to smoking.     

Tramadol concentrations in blood and in cerebrospinal fluid in a neonate

Based on blood and cerebrospinal fluid samples collected in a full-term neonate, the penetration of tramadol in the central nervous system is described. Following intravenous administration of tramadol, a lag time of about 4 h was observed until full blood–brain equilibration was achieved. This pharmacokinetic observation is in line with a recent pharmacodynamic evaluation of the central opioid effects of tramadol in adults.     

Disease control in asthmatic children seen in private practice in Switzerland

ABSTRACT

Background: Asthma is the most common chronic childhood disease in Switzerland with a prevalence of 10%. Asthma has a high economic burden accounting for high medical costs. Assessment of disease control is likely to be of help in the implementation of strategies to improve asthma. Therefore, we aimed to evaluate asthma control and therapy regimens among children in private practice.

Methods: We assessed asthma control as well as therapy regimens in 575 asthmatic children in an experience programme in Switzerland by using an abbreviated questionnaire based on the asthma control questionnaire and the child health questionnaire on Visit 1 and Visit 2.

Results: Good asthma control at Visit 1 was only present in 25.7% of asthmatic children. Occasional asthma symptoms, limitation of physical activity, nocturnal awakening and anxiety of the parent was present in 80.5%, 41.2%, 46.8% and 57% of the children, respectively. After adjustment of therapy regimens at Visit 1, mainly by adding a leukotriene receptor antagonist, asthma control was reported to be much better in 53.4% of the children at Visit 2.

Conclusions: As asthma control is inadequately achieved within a major portion of asthmatic children, it is imperative to find measures to improve asthma control and hence, to reduce the burden of disease.